Related Experiment Video

Updated: Jul 22, 2025

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

Respiratory syncytial virus Prefusion F vaccine

Ann R Falsey1, Edward E Walsh1

  • 1Department of Medicine, University of Rochester, Rochester, NY, USA.

Cell
|July 21, 2023
PubMed

Insights

Respiratory syncytial virus (RSV) causes severe infant respiratory infections and reinfections in adults. Stabilizing the RSV glycoprotein F in its prefusion form was key to developing effective vaccines for older adults.

Area of Science:

  • Virology
  • Vaccinology
  • Immunology

Background:

  • Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness in infants.
  • RSV infections are also common in older adults, leading to significant morbidity.
  • Developing effective RSV vaccines has been a long-standing challenge for decades.

Purpose of the Study:

  • To highlight the critical role of stabilizing the prefusion conformation of the RSV glycoprotein F.
  • To explain how this stabilization enables the development of effective vaccines.
  • To provide insights into the "Bench to Bedside" journey of RSV vaccine development.

Main Methods:

  • Focuses on the structural stabilization of the Respiratory Syncytial Virus (RSV) glycoprotein F.
  • Utilizes advancements in structural biology to capture the prefusion conformation.
  • Details the implications for vaccine design and efficacy.

Main Results:

  • Successful stabilization of the RSV glycoprotein F in its prefusion state.
  • This structural breakthrough is essential for eliciting a protective immune response.
  • Paved the way for the development of novel RSV vaccines.

Conclusions:

  • The stabilization of the prefusion conformation of the RSV glycoprotein F was a critical advancement.
  • This achievement is fundamental to creating effective vaccines against RSV, particularly for vulnerable populations like older adults.
  • Represents a significant milestone in combating RSV-related respiratory infections.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.8K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.0K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
250
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
165
Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
694
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
278